Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Abstract

In this trial, patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control. Greater benefits were seen in patients with higher baseline levels of eosinophils. Hypereosinophilia was observed in some patients. (Funded by Sanofi and Regeneron Pharmaceuticals; LIBERTY ASTHMA QUEST ClinicalTrials.gov number, NCT02414854 .).

Keywords

DupilumabMedicineAsthmaMonoclonal antibodyMonoclonalClinical efficacyInterleukinImmunologyInternal medicineAntibodyCytokine

Affiliated Institutions

Related Publications

Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Daniel Berg , N Davidson , Ralf Kühn +6 more

We have characterized the progressive stages of chronic intestinal inflammation that develops spontaneously in specific pathogen-free (SPF) mice with a targeted disruption in th...

1996 Journal of Clinical Investigation 1129 citations

Publication Info

Year: 2018
Type: article
Volume: 378
Issue: 26
Pages: 2486-2496
Citations: 1777
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1777

OpenAlex

Cite This

APA Style

                            
                                
                                    Mario Castro, 
                                
                                    Jonathan Corren, 
                                
                                    Ian Pavord
                                
                                et al.
                            
                            (2018). 
                            Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. 
                            New England Journal of Medicine
                            , 378
                            (26)
                            , 2486-2496.
                            https://doi.org/10.1056/nejmoa1804092
                        

Identifiers

DOI: 10.1056/nejmoa1804092